Toll Free: 1-888-928-9744
Published: Nov, 2014 | Pages:
36 | Publisher: Global Markets Direct
Industry: Pharmaceutical | Report Format: Electronic (PDF)
EpiVax, Inc. - Product Pipeline Review - 2014 Summary Global Markets Direct's, 'EpiVax, Inc. - Product Pipeline Review - 2014', provides an overview of the EpiVax, Inc.'s pharmaceutical research and development focus. This report provides comprehensive information on the current therapeutic developmental pipeline of EpiVax, Inc.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides brief overview of EpiVax, Inc. including business description, key information and facts, and its locations and subsidiaries - The report reviews current pipeline of EpiVax, Inc.'s human therapeutic division and enlists all their major and minor projects - The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones - Special feature on out-licensed and partnered product portfolio - The report summarizes all the dormant and discontinued pipeline projects - Latest company statement - Latest news and deals relating to the EpiVax, Inc.'s pipeline products Reasons to buy - Evaluate EpiVax, Inc.'s strategic position with total access to detailed information on its product pipeline - Assess the growth potential of EpiVax, Inc. in its therapy areas of focus - Identify new drug targets and therapeutic classes in the EpiVax, Inc.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas - Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps - Develop strategic initiatives by understanding the focus areas of EpiVax, Inc. and exploit collaboration and partnership opportunities - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Plan mergers and acquisitions effectively by identifying the most promising pipeline of EpiVax, Inc. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Explore the dormant and discontinued projects of EpiVax, Inc. and identify potential opportunities in those areas - Avoid Intellectual Property Rights related issues
Table of Contents Table of Contents 2 List of Tables 4 List of Figures 4 EpiVax, Inc. Snapshot 5 EpiVax, Inc. Overview 5 Key Information 5 Key Facts 5 EpiVax, Inc. - Research and Development Overview 6 Key Therapeutic Areas 6 EpiVax, Inc. - Pipeline Review 9 Pipeline Products by Stage of Development 9 Pipeline Products - Monotherapy 10 EpiVax, Inc. - Pipeline Products Glance 11 EpiVax, Inc. - Early Stage Pipeline Products 11 Preclinical Products/Combination Treatment Modalities 11 Discovery Products/Combination Treatment Modalities 12 EpiVax, Inc. - Drug Profiles 13 Deimmunized FVIII 13 Product Description 13 Mechanism of Action 13 R&D Progress 13 Epi-13 14 Product Description 14 Mechanism of Action 14 R&D Progress 14 helicobacter pylori infection vaccine 15 Product Description 15 Mechanism of Action 15 R&D Progress 15 influenza vaccine [H1N1] 16 Product Description 16 Mechanism of Action 16 R&D Progress 16 onabotulinumtoxin A 18 Product Description 18 Mechanism of Action 18 R&D Progress 18 smallpox vaccine 19 Product Description 19 Mechanism of Action 19 R&D Progress 19 Synthetic Peptides for Allergy 20 Product Description 20 Mechanism of Action 20 R&D Progress 20 Synthetic Peptides for Pompe disease 21 Product Description 21 Mechanism of Action 21 R&D Progress 21 tuberculosis vaccine 22 Product Description 22 Mechanism of Action 22 R&D Progress 22 TuliVax 23 Product Description 23 Mechanism of Action 23 R&D Progress 23 equine encephalitis vaccine 24 Product Description 24 Mechanism of Action 24 R&D Progress 24 influenza vaccine (H7N9) 25 Product Description 25 Mechanism of Action 25 R&D Progress 25 EpiVax, Inc. - Pipeline Analysis 26 EpiVax, Inc. - Pipeline Products by Target 26 EpiVax, Inc. - Pipeline Products by Route of Administration 27 EpiVax, Inc. - Pipeline Products by Molecule Type 28 EpiVax, Inc. - Pipeline Products by Mechanism of Action 29 EpiVax, Inc. - Recent Pipeline Updates 30 EpiVax, Inc. - Dormant Projects 31 EpiVax, Inc. - Company Statement 32 EpiVax, Inc. - Locations And Subsidiaries 34 Head Office 34 Appendix 35 Methodology 35 Coverage 35 Secondary Research 35 Primary Research 35 Expert Panel Validation 35 Contact Us 36 Disclaimer 36
List of Tables EpiVax, Inc., Key Information 5 EpiVax, Inc., Key Facts 5 EpiVax, Inc. - Pipeline by Indication, 2014 8 EpiVax, Inc. - Pipeline by Stage of Development, 2014 9 EpiVax, Inc. - Monotherapy Products in Pipeline, 2014 10 EpiVax, Inc. - Preclinical, 2014 11 EpiVax, Inc. - Discovery, 2014 12 EpiVax, Inc. - Pipeline by Target, 2014 26 EpiVax, Inc. - Pipeline by Route of Administration, 2014 27 EpiVax, Inc. - Pipeline by Molecule Type, 2014 28 EpiVax, Inc. - Pipeline Products by Mechanism of Action, 2014 29 EpiVax, Inc. - Recent Pipeline Updates, 2014 30 EpiVax, Inc. - Dormant Developmental Projects,2014 31
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.